On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine

Janina Baranowska-Kortylewicz, Glenn V. Dalrymple, Katherine A. Harrison, Karen P. Holdeman, John G Sharp, Samuel Monroe Cohen, Robert P. Lieberman, Martin H. Schneiderman, Sydney R. Clausen, Debra Hoffman, Jing Lai, G. Sue Schneiderman, Lynn Helseth

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.

Original languageEnglish (US)
Pages (from-to)925-933
Number of pages9
JournalActa Oncologica
Volume35
Issue number7
DOIs
StatePublished - Jan 1 1996

Fingerprint

Deoxyuridine
Swine
Safety
Idoxuridine
Blood Cell Count
Liver
Radiation Effects
Radio
Intravenous Injections
Radioactivity
Histology
Reference Values
Pharmacokinetics
Kidney
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine. / Baranowska-Kortylewicz, Janina; Dalrymple, Glenn V.; Harrison, Katherine A.; Holdeman, Karen P.; Sharp, John G; Cohen, Samuel Monroe; Lieberman, Robert P.; Schneiderman, Martin H.; Clausen, Sydney R.; Hoffman, Debra; Lai, Jing; Schneiderman, G. Sue; Helseth, Lynn.

In: Acta Oncologica, Vol. 35, No. 7, 01.01.1996, p. 925-933.

Research output: Contribution to journalArticle

Baranowska-Kortylewicz, J, Dalrymple, GV, Harrison, KA, Holdeman, KP, Sharp, JG, Cohen, SM, Lieberman, RP, Schneiderman, MH, Clausen, SR, Hoffman, D, Lai, J, Schneiderman, GS & Helseth, L 1996, 'On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine', Acta Oncologica, vol. 35, no. 7, pp. 925-933. https://doi.org/10.3109/02841869609104047
Baranowska-Kortylewicz, Janina ; Dalrymple, Glenn V. ; Harrison, Katherine A. ; Holdeman, Karen P. ; Sharp, John G ; Cohen, Samuel Monroe ; Lieberman, Robert P. ; Schneiderman, Martin H. ; Clausen, Sydney R. ; Hoffman, Debra ; Lai, Jing ; Schneiderman, G. Sue ; Helseth, Lynn. / On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine. In: Acta Oncologica. 1996 ; Vol. 35, No. 7. pp. 925-933.
@article{02772cde73384ca493c886c39c409ef0,
title = "On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine",
abstract = "To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.",
author = "Janina Baranowska-Kortylewicz and Dalrymple, {Glenn V.} and Harrison, {Katherine A.} and Holdeman, {Karen P.} and Sharp, {John G} and Cohen, {Samuel Monroe} and Lieberman, {Robert P.} and Schneiderman, {Martin H.} and Clausen, {Sydney R.} and Debra Hoffman and Jing Lai and Schneiderman, {G. Sue} and Lynn Helseth",
year = "1996",
month = "1",
day = "1",
doi = "10.3109/02841869609104047",
language = "English (US)",
volume = "35",
pages = "925--933",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - On the safety of 5-[125I]iodo-2′-deoxyuridine. Preclinical evaluation in swine

AU - Baranowska-Kortylewicz, Janina

AU - Dalrymple, Glenn V.

AU - Harrison, Katherine A.

AU - Holdeman, Karen P.

AU - Sharp, John G

AU - Cohen, Samuel Monroe

AU - Lieberman, Robert P.

AU - Schneiderman, Martin H.

AU - Clausen, Sydney R.

AU - Hoffman, Debra

AU - Lai, Jing

AU - Schneiderman, G. Sue

AU - Helseth, Lynn

PY - 1996/1/1

Y1 - 1996/1/1

N2 - To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.

AB - To increase tumor incorporation and minimize hepatic degradation of radio-IUdR, compartmental administration routes are being considered as an alternative to intravenous (i.v.) injections. Although there are significant data on the biodistribution and some reports on radiotoxicity of i.v.-administered 125IUdR, similar results for other routes of delivery are not available. We have undertaken a series of experiments intended to examine radiation effects of 125IUdR after intravesical (3 swine; eight 3 mCi doses at 4-day intervals), intracarotid (3 swine; two 10 mCi doses at 2-week intervals), and intra-aortic (5 swine, single dose of 10 mCi) administration in a swine model. Liver, renal functions, and complete blood counts were monitored throughout the duration of the experiment. Pharmacokinetics, systemic distribution of radioactivity and metabolites were measured. The normal tissue 125IUdR uptake and histology were determined after necropsy. No adverse systemic effects were identified. Clinical observations, laboratory data, and necropsy results were within normal range.

UR - http://www.scopus.com/inward/record.url?scp=0030299853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030299853&partnerID=8YFLogxK

U2 - 10.3109/02841869609104047

DO - 10.3109/02841869609104047

M3 - Article

C2 - 9004773

AN - SCOPUS:0030299853

VL - 35

SP - 925

EP - 933

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7

ER -